Researchers stated that an experimental vaccine produced by GeoVax Labs Inc. successfully promoted the formation of antibodies that target two separate locations on the virus in a small pilot study and has been forwarded to mid-stage clinical testing.

The following is an overview of several recent COVID-19 research studies. They contain research that requires more investigation to verify the results and has not yet been validated by critical analysis. According to the study team from City of Hope National Medical Center in Duarte, California, 94 percent generated antibodies against the spike and the nucleocapsid protein.

Other immune system cells, such as T cells, which defend against serious infection, also responded well. The vaccine, which employs a different version of a harmless virus to send commands to the immune system, was given to 56 volunteers in the research, which was published on Wednesday in The Lancet Microbe.

The alterations appeared six to thirteen days after the patients began taking the medicine, according to a study published in The New England Journal of Medicine on Wednesday. The same alterations were found in four of 45 individuals in a previous research study of the medicine, according to Rebecca Rockett, the report’s principal author from the University of Sydney in Australia.

“However, our study highlights the need for better surveillance and further research to ensure that novel antiviral treatments remain effective and if resistance develops, it is not transmitted into the community” Rebecca Rockett stated.